SLC2A1 and epilepsy: A KD is not only a therapeutic option in pharmacoresistant epilepsy, but is advocated in certain inborn errors of metabolism, such as a pyruvate dehydrogenase deficiency, a glucose transporter 1 (GLUT1) deficiency, hyperinsulinism, respiratory chain defects, and others [52].